"Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcin"...
Mechanism Of Action
Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.
Increases in blood pressure have been observed and are related to steady-state trough plasma pazopanib concentrations.
The QT prolongation potential of pazopanib was assessed in a randomized, blinded, parallel trial (N = 96) using moxifloxacin as a positive control. Pazopanib 800 mg was dosed under fasting conditions on Days 2 to 8 and 1,600 mg was dosed on Day 9 after a meal in order to increase exposure to pazopanib and its metabolites. No large changes (i.e., > 20 msec) in QTc interval following the treatment of pazopanib were detected in this QT trial. The trial was not able to exclude small changes ( < 10 msec) in QTc interval, because assay sensitivity below this threshold ( < 10 msec) was not established in this trial [see WARNINGS AND PRECAUTIONS].
Pazopanib is absorbed orally with median time to achieve peak concentrations of 2 to 4 hours after the dose. Daily dosing at 800 mg results in geometric mean AUC and Cma x of 1,037 mcg•h/mL and 58.1 mcg/mL (equivalent to 132 μM), respectively. There was no consistent increase in AUC or Cma x at pazopanib doses above 800 mg.
Administration of a single pazopanib 400-mg crushed tablet increased AUC(0-72) by 46% and Cma x by approximately 2 fold and decreased Tma x by approximately 2 hours compared with administration of the whole tablet. These results indicate that tghe bioavailability and the rate of pazopanib oral absorption are increased after administration of the crushed tablet relative to administration of the whole tablet. Therefore, due to this potential for increased exposure, tablets of VOTRIENT should not be crushed.
Systemic exposure to pazopanib is increased when administered with food. Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and Cmax. Therefore, pazopanib should be administered at least 1 hour before or 2 hours after a meal [see DOSAGE AND ADMINISTRATION].
Binding of pazopanib to human plasma protein in vivo was greater than 99% with no concentration dependence over the range of 10 to 100 mcg/mL. In vitro studies suggest that pazopanib is a substrate for P-gp and BCRP.
In vitro studies demonstrated that pazopanib is metabolized by CYP3A4 with a minor contribution from CYP1A2 and CYP2C8.
Pazopanib has a mean half-life of 30.9 hours after administration of the recommended dose of 800 mg. Elimination is primarily via feces with renal elimination accounting for < 4% of the administered dose.
Mild hepatic impairment was defined as either total bilirubin WNL with ALT > ULN or bilirubin > 1 X to 1.5 X ULN regardless of the ALT value. The median steady-state pazopanib Cmax and AUC(0-24) after a once-daily dose of 800 mg/day in patients (N = 12) with mild impairment were 34 mcg/mL (range: 11 to 104) and 774 mcg•h/mL (range: 215 to 2,034), respectively. These were in a similar range as the median steady-state pazopanib Cmax and AUC(0-24) in patients (N = 18) with no hepatic impairment (52 mcg/mL, range: 17 to 86 and 888 mcg•h/mL, range: 346 to 1,482, respectively) [see DOSAGE AND ADMINISTRATION].
Moderate hepatic impairment was defined as total bilirubin > 1.5 X to 3 X ULN regardless of the ALT value. The maximum tolerated pazopanib dose in patients with moderate impairment was 200 mg once daily. The median (N = 11) steady-state Cmax with that regimen was 22 mcg/mL (range: 4.2 to 33), and the median AUC(0-24) was 257 mcg•h/mL (range: 66 to 488). These values were approximately 43% and 29% of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function (N = 18) [see DOSAGE AND ADMINISTRATION].
Severe hepatic impairment was defined as total bilirubin > 3 X ULN regardless of the ALT value. Median exposures in patients with severe hepatic impairment receiving 200 mg once daily (N = 14) were unexpectedly lower than those observed in patients with moderate hepatic impairment receiving 200 mg once daily. The median steady-state Cmax was 9.4 mcg/mL (range: 2.4 to 24), and the median AUC(0-24) was 131 mcg•h/mL (range: 47 to 473). These values were approximately 18% and 15% of the corresponding median values after administration of 800 mg once daily in patients with normal hepatic function. Despite the observed concentrations, the dose of 200 mg was not well tolerated in patients with severe hepatic impairment. Use of VOTRIENT is not recommended in patients with severe hepatic impairment [see Use in Specific Populations].
Coadministration of multiple doses of oral pazopanib 400 mg with multiple doses of oral ketoconazole 400 mg (strong CYP3A4/P-gp inhibitor) resulted in a 1.7-fold increase in the AUC(0-24) and a 1.5-fold increase in the Cmax of pazopanib compared with pazopanib administered alone. Concurrent administration of a single dose of pazopanib eye drops with ketoconazole in healthy volunteers resulted in a 2fold and 1.5-fold increase in mean AUC(0-t) and Cmax values, respectively [see DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS].
Administration of 1,500 mg lapatinib, a substrate and weak inhibitor of CYP3A4, P-gp, and BCRP, with 800 mg pazopanib resulted in an approximately 50% to 60% increase in mean pazopanib AUC(0-24) and Cmax compared with administration of 800 mg pazopanib alone.
In vitro studies with human liver microsomes showed that pazopanib inhibited the activities of CYP enzymes 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, 2D6, and 2E1. Potential induction of human CYP3A4 was demonstrated in an in vitro human pregnane X receptor (PXR) assay. Clinical pharmacology studies, using pazopanib 800 mg once daily, have demonstrated that pazopanib does not have a clinically relevant effect on the pharmacokinetics of caffeine (CYP1A2 probe substrate), warfarin (CYP2C9 probe substrate), or omeprazole (CYP2C19 probe substrate) in cancer patients. Pazopanib resulted in an increase of approximately 30% in the mean AUC and Cmax of midazolam (CYP3A4 probe substrate) and increases of 33% to 64% in the ratio of dextromethorphan to dextrorphan concentrations in the urine after oral administration of dextromethorphan (CYP2D6 probe substrate). Coadministration of pazopanib 800 mg once daily and paclitaxel 80 mg/m² (CYP3A4 and CYP2C8 substrate) once weekly resulted in a mean increase of 26% and 31% in paclitaxel AUC and Cmax, respectively [see DRUG INTERACTIONS].
Pazopanib exhibits pH-dependent solubility. In a drug interaction trial in patients with solid tumors, concomitant administration of pazopanib with esomeprazole, a PPI, decreased the exposure of pazopanib by approximately 40% (AUC and Cmax).
In vitro studies also showed that pazopanib inhibits UGT1A1 and organic anion-transporting polypeptide (OATP1B1) with IC50s of 1.2 and 0.79 μM, respectively. Pazopanib may increase concentrations of drugs eliminated by UGT1A1 and OATP1B1.
Pazopanib can increase serum total bilirubin levels [see WARNINGS AND PRECAUTIONS]. In vitro studies showed that pazopanib inhibits UGT1A1, which glucuronidates bilirubin for elimination. A pooled pharmacogenetic analysis of 236 Caucasian patients evaluated the TA-repeat polymorphism of UGT1A1 and its potential association with hyperbilirubinemia during pazopanib treatment. In this analysis, the (TA)7/(TA)7 genotype (UGT1A1*28/*28) (underlying genetic susceptibility to Gilbert's syndrome) was associated with a statistically significant increase in the incidence of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes.
Renal Cell Carcinoma
The safety and efficacy of VOTRIENT in renal cell carcinoma (RCC) were evaluated in a randomized, double-blind, placebo-controlled, multicenter, Phase 3 trial. Patients (N = 435) with locally advanced and/or metastatic RCC who had received either no prior therapy or one prior cytokine-based systemic therapy were randomized (2:1) to receive VOTRIENT 800 mg once daily or placebo once daily. The primary objective of the trial was to evaluate and compare the 2 treatment arms for progression-free survival (PFS); the secondary endpoints included overall survival (OS), overall response rate (RR), and duration of response.
Of the total of 435 patients enrolled in this trial, 233 patients had no prior systemic therapy (treatmentna´ve subgroup) and 202 patients received one prior IL-2 or INFα-based therapy (cytokine-pretreated subgroup). The baseline demographic and disease characteristics were balanced between the arms receiving VOTRIENT and placebo. The majority of patients were male (71%) with a median age of 59 years. Eighty-six percent of patients were Caucasian, 14% were Asian, and less than 1% were other. Forty-two percent were ECOG performance status 0 and 58% were ECOG performance status 1. All patients had clear cell histology (90%) or predominantly clear cell histology (10%). Approximately 50% of all patients had 3 or more organs involved with metastatic disease. The most common metastatic sites at baseline were lung (74%), lymph nodes (56%), bone (27%), and liver (25%).
A similar proportion of patients in each arm were treatment-na´ve and cytokine-pretreated (see Table 5). In the cytokine-pretreated subgroup, the majority (75%) had received interferon-based treatment. Similar proportions of patients in each arm had prior nephrectomy (89% and 88% for VOTRIENT and placebo, respectively).
The analysis of the primary endpoint PFS was based on disease assessment by independent radiological review in the entire trial population. Efficacy results are presented in Table 5 and Figure 1.
Table 5:Efficacy Results in RCC Patients by
|Endpoint/Trial Population||VOTRIENT||Placebo||HR (95% CI)|
|Overall ITT||N = 290||N = 145|
|Median (months)||9.2||4.2||0.46a (0.34, 0.62)|
|Treatment-naive subgroup||N = 155 (53%)||N = 78 (54%)|
|Median (months)||11.1||2.8||0.40 (0.27, 0.60)|
|Cytokine pre-treated subgroup||N = 135 (47%)||N = 67 (46%)|
|Median (months)||7.4||4.2||0.54 (0.35, 0.84)|
|Response Rate (CR + PR)||N = 290||N = 145|
|% (95% CI)||30 (25.1, 35.6)||3 (0.5, 6.4)||-|
|Duration of response|
|Median (weeks) (95% CI)||58.7 (52.1, 68.1)||-b||-|
|HR = Hazard Ratio; ITT = Intent to Treat; PFS = Progression-free
Survival; CR = Complete Response; PR = Partial Response.
aP value < 0.001.
bThere were only 5 objective responses.
Figure 1:Kaplan-Meier Curve for Progression-free
Survival in RCC by Independent Assessment for the Overall Population (Treatment
- naive and Cytokine Pre-treated Populations)
At the protocol-specified final analysis of OS, the median OS was 22.9 months for patients randomized to VOTRIENT and 20.5 months for the placebo arm [HR = 0.91 (95% CI: 0.71, 1.16)]. The median OS for the placebo arm includes 79 patients (54%) who discontinued placebo treatment because of disease progression and crossed over to treatment with VOTRIENT. In the placebo arm, 95 (66%) patients received at least one systemic anti-cancer treatment after progression compared with 88 (30%) patients randomized to VOTRIENT.
Soft Tissue Sarcoma
The safety and efficacy of VOTRIENT in patients with STS were evaluated in a randomized, double-blind, placebo-controlled, multicenter trial. Patients (N = 369) with metastatic STS who had received prior chemotherapy, including anthracycline treatment, or were unsuited for such therapy, were randomized (2:1) to receive VOTRIENT 800 mg once daily or placebo. Patients with gastrointestinal stromal tumors (GIST) or adipocytic sarcoma were excluded from the trial. Randomization was stratified by the factors of WHO performance status (WHO PS) 0 or 1 at baseline and the number of lines of prior systemic therapy for advanced disease (0 or 1 versus 2+). Progression-free survival (PFS) was assessed by independent radiological review. Other efficacy endpoints included overall survival (OS), overall response rate, and duration of response.
The majority of patients were female (59%) with a median age of 55 years. Seventy-two percent of patients were Caucasian, 22% were Asian, and 6% were other. Forty-three percent of patients had leiomyosarcoma, 10% had synovial sarcoma, and 47% had other soft tissue sarcomas. Fifty-six percent of patients had received 2 or more lines of prior systemic therapy and 44% had received 0 or 1 lines of prior systemic therapy. The median duration of treatment was 4.5 months for patients on the pazopanib arm and 1.9 months for patients on the placebo arm.
Efficacy results are presented in Table 6 and Figure 2.
Table 6: Efficacy Results in STS Patients by Independent
|Endpoint/Trial Population||VOTRIENT||Placebo||HR (95% CI)|
|Overall ITT||N = 246||N = 123||0.35a|
|Median (months)||4.6||1.6||(0.26, 0.48)|
|Leiomyosarcoma subgroup||N = 109||N = 49||0.37|
|Median (months)||4.6||1.9||(0.23, 0.60)|
|Synovial sarcoma subgroup||N = 25||N = 13||0.43|
|Median (months)||4.1||0.9||(0.19, 0.98)|
|‘Other soft tissue sarcoma’ subgroup||N = 112||N = 61||0.39|
|Median (months)||4.6||1.0||(0.25, 0.60)|
|Response Rate (CR + PR)|
|% (95% CI)||4 (2.3, 7.9)b||0 (0.0, 3.0)||-|
|Duration of response|
|Median (months) (95% CI)||9.0 (3.9, 9.2)|
|HR = Hazard Ratio; ITT = Intent
to Treat; PFS = Progression-free Survival; CR = Complete Response; PR = Partial
aP value < 0.001.
bThere were 11 partial responses and 0 complete responses.
Figure 2: Kaplan-Meier Curve
for Progression-free Survival in STS by Independent Assessment for the Overall
At the protocol-specified final analysis of OS, the median OS was 12.6 months for patients randomized to VOTRIENT and 10.7 months for the placebo arm [HR = 0.87 (95% CI: 0.67, 1.12)].
Last reviewed on RxList: 10/26/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Votrient Information
Votrient - User Reviews
Votrient User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.